Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf vs BLES for RDS in Preterm Infants
NCT01709409Phase 3Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2013
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Poractant alfa in respiratory distress syndrome (RDS), sponsored by Ottawa Hospital Research Institute. Started Mar 2013; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT01709409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709409.